T1DM

Intensive glycemic control

DCCT

Strict glycemic control prevents upto 70% of microvascular complications particularly retinopathy

EDIC

long term follow up to the DCCT  - intensive glycemic control reduced the subsequent risk of CV events as well

42% and severe CV events by 57% at 11 yrs among pts with T1DM

Metabolic memory

T1GER

Among children and young adults with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin production and less exogenous insulin use than placebo.

DEPICT-1

In patients with type 1 diabetes, the addition of Dapagliflozin leads to a decrease in HbA1c over a 52-week period, promotes weight loss, and allows for a decrease in the dose of insulin administered, however,

an increase in incidence of DKA

T2DM

Intensive glycemic control

UKPDS 33

Intensive glycemic control (FBS<108) that reduces  Hba1c by 11% over 10 years associated with a 25% reduction microvascular complications ,

NO effect on macrovascular disease or mortality among pts with T2DM

ADVANCE

Intensive glycemic control targeting HbA1c ≤6.5% improves microvascular outcomes but has